Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in HER2-positive Advanced Breast Cancer
NCT06663748Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of anvatabart opadotin in breast cancer, sponsored by Henan Cancer Hospital. Started Jun 2025; status: recruiting.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06663748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663748.